View More Recent Stories
-
Capricor Therapeutics (CAPR) announces FDA has scheduled Pre-BLA meeting for deramiocel to treat DMD
-
Capricor Therapeutics (CAPR) Files $150M Mixed Shelf
-
Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002 Program
